The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Use of Linezolid, an Oxazolidinone, in the Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections
Abstract
We report our experience with linezolid in an investigation of its use against resistant gram-positive bacterial infections. Fifteen patients who had renal failure (n=6), recent liver transplantation (n=5) or surgery (n=6), cancer (n=3), endocarditis (n=2), or human immunodeficiency virus infection (n=1), along with infections due to vancomycin-resistant enterococcus (VRE), and 2 patients with infections due to methicillin-resistant Staphylococcus species who had adverse reactions to vancomycin were treated with linezolid (600 mg every 12 h for 5-42 days (mean+/-SD, 20.5+/-3.5 days). Abscess drainage or prosthetic device removal was undertaken. Microbiological cure occurred in all 10 patients who completed therapy, and all 7 patients alive at follow-up were free of infection. No deaths were attributable to the index infection. Adverse events associated with linezolid use were mild leukopenia in 1 patient and nausea in another. It appears that administration of linezolid, in conjunction with surgical intervention or device removal, is an effective treatment option for serious resistant gram-positive bacterial infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989.
Banerjee, S. N., Emori, T. G., Culver, D. H., Gaynes, R. P., Jarvis, W. R., Horan, T., Edwards, J. R., Tolson, J., Henderson, T., Martone, W. J., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90349-3 · Cited by 880
Cited by
Molecular mechanisms that confer antibacterial drug resistance
Walsh, C. (2000) · Nature · doi:10.1038/35021219 · Cited by 1,578
Oxazolidinones: activity, mode of action, and mechanism of resistance
Bozdogan, B., & Appelbaum, P. C. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.11.003 · Cited by 403
Diekema, D. J., & Jones, R. N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06964-1 · Cited by 378
Cunha, B. A. (2001) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70309-6 · Cited by 358
Emergence and management of drug-resistant enterococcal infections
Arias, C. A., & Murray, B. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.637 · Cited by 294
In Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid)
Andes, D., van Ogtrop, M. L., Peng, J., & Craig, W. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3484-3489.2002 · Cited by 278
Vancomycin‐Resistant Enterococci: Mechanisms and Clinical Observations
Gold, H. S. (2001) · Clinical Infectious Diseases · doi:10.1086/321815 · Cited by 258
Falagas, M. E. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl219 · Cited by 167
“2000 ( 27 ) NA abdominal aortic repair, DM, ARF NA VRE VAN, ALF (NA) NA 42 cure 1 none”
Successful Treatment of Vancomycin-Resistant Enterococcus Endocarditis with Oral Linezolid
Babcock, H. M., Ritchie, D. J., Christiansen, E., Starlin, R., Little, R., & Stanley, S. (2001) · Clinical Infectious Diseases · doi:10.1086/319986 · Cited by 113
Linezolid therapy for infective endocarditis
Muñoz, P., Rodríguez-Creixéms, M., Moreno, M., Marín, M., Ramallo, V., Bouza, E., & GAME Study Group (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01585.x · Cited by 68
Metadata
- Authors
- Chien, J. W., Kucia, M. L., & Salata, R. A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-01-01
- Volume
- 30
- Issue
- 1
- Pages
- 146-151
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2158780065
- Cited by
- 190
- References
- 1
- FWCI
- 20.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.